These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26660679)

  • 1. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation.
    Uribe LA; Nguyen N; Kim L; Trinh HN; Wong C; Wong C; Nguyen LH; Nguyen MH
    Dig Dis Sci; 2016 Feb; 61(2):618-25. PubMed ID: 26660679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy.
    Nguyen NH; Nguyen V; Trinh HN; Lin B; Nguyen MH
    Clin Gastroenterol Hepatol; 2013 May; 11(5):565-71. PubMed ID: 23333662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
    J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study.
    Zhang S; Ristau JT; Trinh HN; Garcia RT; Nguyen HA; Nguyen MH
    Dig Dis Sci; 2012 May; 57(5):1373-83. PubMed ID: 22466077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low treatment rates in patients meeting guideline criteria in diverse practice settings.
    Kim LH; Nguyen VG; Trinh HN; Li J; Zhang JQ; Nguyen MH
    Dig Dis Sci; 2014 Sep; 59(9):2091-9. PubMed ID: 25060778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
    Wong RJ; Kaufman HW; Niles JK; Kapoor H; Gish RG
    Clin Infect Dis; 2023 Feb; 76(3):e791-e800. PubMed ID: 35594550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.
    Gao S; Fan YC; Zhao J; Sun FK; Han J; Zhao ZH; Wang K
    Liver Int; 2014 Aug; 34(7):e229-37. PubMed ID: 24112455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
    Juday T; Tang H; Harris M; Powers AZ; Kim E; Hanna GJ
    J Gen Intern Med; 2011 Mar; 26(3):239-44. PubMed ID: 20978862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
    Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
    J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.
    Peng CY; Hsieh TC; Hsieh TY; Tseng KC; Lin CL; Su TH; Tseng TC; Lin HH; Wang CC; Kao JH
    J Formos Med Assoc; 2015 Apr; 114(4):308-13. PubMed ID: 24315616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B.
    Huang DQ; Lee DH; Le MH; Le A; Yeo YH; Trinh HN; Chung M; Nguyen V; Johnson T; Zhang JQ; Wong C; Wong C; Li J; Cheung R; Nguyen MH
    Dig Dis; 2023; 41(1):115-123. PubMed ID: 36070707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.